Integrating Mass Spectrometry-based Proteomics and Lipidomics Reveals Biomarkers and Altered Signaling Pathways During Progressive Neurodegeneration in Niemann-Pick Disease, type C1

Proteomics Interest Group Advances in mass spectrometry technology have enabled large-scale differential analysis of proteins and lipids to investigate altered pathways in human disease. Our laboratory studies Niemann-Pick Disease, type C1 (NPC1) a lysosomal storage disorder with visceral involvement and progressive cerebellar neurodegeneration. Using a combination of differential proteomics, lipidomics and mass spectrometry imaging, we have identified new candidate biomarkers in a mouse model of NPC1. These alterations now provide a basis for evaluation in NPC1 patients and also can be used for therapeutic development. Several examples will be presented.For more information go tohttp://proteome.nih.govAir date: 2/8/2019 1:00:00 PM
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video